Omics disciplines such as metabolomics, lipidomics, and proteomics offer a wide range of applications in the pharmaceutical industry, driving advancements in drug research and development. These omics applications are revolutionizing the pharmaceutical industry, enabling the development of safer, more effective, and personalized treatments for patients.
Research on lipid-related diseases: Identifying lipid profile changes linked to dyslipidemias, cardiovascular diseases, neurodegenerative disorders, and cancer.
Development of targeted therapies: Exploring lipids as targets for innovative drug development.
Lipid biomarker development: Using lipids as indicators in efficacy, toxicity, and disease progression studies.
Cell membrane studies: Analyzing drug effects on membrane structure and function, highlighting the critical role of lipids.
Drug mechanism of action: Identifying drug-affected metabolic pathways to understand drug action.
Biomarker discovery: Identifying disease-related metabolites for early diagnosis, prognosis, and therapy monitoring.
ADME-Tox studies: Analyzing metabolites to assess pharmaceutical metabolism, distribution, elimination, and toxicity.
Personalized medicine: Designing personalized treatments to enhance efficacy and minimize side effects.
Validation of therapeutic targets: Identifying key disease-related proteins as targets for drug development.
Discovery of protein biomarkers: Detecting proteins that indicate health, disease progression, and treatment response.
Design of biological therapies: Developing monoclonal antibodies, recombinant proteins, and gene therapies targeting proteins.
Studies on drug resistance: Understanding molecular mechanisms of resistance, like protein overexpression.
At oloBion, we provide cutting-edge omics services designed to empower researchers in the Pharmaceutical & Biotechnology industry. With our state-of-the-art technology and the expertise of our team, we help you unlock the full potential of your analytes, driving discovery, innovation, and impactful solutions. Our portfolio includes both Untargeted and Targeted OMICS services, as well as ADME-DMPK assays, all tailored to meet the specific needs of your research.
Technique: LC-MS/MS
Untargeted lipidomics analysis for the identification of lipids by LC-MS/MS.The Identification includes a list with superclass, class, lipid name, and InChIKey.
Technique: LC-MS/MS
Untargeted lipidomics analysis for the identification of short chain fatty acids by LC-MS/MS. The indentification includes a list with superclass, class, lipid name, and InChIKey.
Technique: LC-MS/MS
Untargeted lipidomics analysis for the identification of lipids by LC-MS/MS, including oxylipins. The Identification includes a list with superclass, class, lipid name, and InChIKey.
Technique: LC-MS/MS
Untargeted lipidomics analysis for the identification of lipids by LC-MS/MS.The Identification includes a list with superclass, class, lipid name, and InChIKey.
Is an emerging discipline that combines lipidomic analysis with pharmacology to better understand the interaction between drugs and the body’s lipid profiles. Its integration complements ADME-Tox and pharmacometabolomics studies, enabling a deeper characterization of compound bioavailability, metabolism, and toxicity.
Selection of Lipid Profiles and Biomarkers:
Targeted lipidomics analysis for the quantification of total fatty acids (FW) (g/100g)
Technique: LC-MS/MS
Target Lipidomics analysis for the identification of specific lipid(s) according to customer requirements
Technique: LC-MS/MS
NextGen proteomics analysis by LC-MS/MS for the identification of proteins in plasma. The identification includes the family and name of the protein.
Technique: LC-MS/MS
NextGen proteomics analysis by LC-MS/MS for the identification of proteins in stool. The identification includes the family and name of the protein.
Technique: LC-MS/MS
NextGen proteomics analysis by LC-MS/MS for the identification of proteins. The identification includes the family and name of the protein.
Is an emerging discipline that studies the interaction of drugs with the proteome, enabling a better understanding of mechanisms of action, resistance, and treatment toxicity. Its integration complements ADME-Tox and pharmacometabolomics studies, providing key information for the optimization of personalized therapies.
Selection of Proteins and Biomarkers
Technique: LC-MS/MS
Target Proteomics analysis for the identification of specific protein(s) according to customer requirements
Metabolism is the biotransformation process that drugs undergo in the body, usually as part of the strategy of elimination. A wide group of drug metabolizing enzymes are responsible for the biotransformation of drugs, mainly into more hydrophilic structures, ready for the excretion in urine or bile. Several organs can be involved in this process, the liver being the main one.
For the assessment of metabolic stability, new compounds are incubated in vitro in presence of liver subcellular fractions such as microsomes or in presence of hepatocytes. The results can be extrapolated to estimate the in vivo hepatic clearance.
Depending on the chemical structure, in the case of groups susceptible of hydrolysis, metabolic stability in plasma should also be checked.
Furthermore, the specific enzymes responsible for the metabolism of investigational drugs should be identified, as well as the chemical structure of the metabolites formed as a result of metabolizing enzymes action.
Preclinical pharmacokinetics plays an important role in the Drug Discovery and Development process. Regulatory agencies require preclinical pharmacokinetic data to assess the efficacy and safety of new candidates before their approval for clinical trials.
Pharmacokinetics assessment is present throughout all the stages of the drug development process. Preclinical pharmacokinetics helps, among others, screen out compounds, understand the relationship between the pharmacological activity and exposure in plasma and tissue of action, identify the dosage range that achieves therapeutic levels while minimizing the risk of toxicity, and predict human pharmacokinetics.
Experiments can be designed for initial pharmacokinetic screening of compounds, renal excretion, in vivo tissue distribution or for assessment of the influence of different variables (dose, formulation, sex, food) at later stages.
Only the unbound fraction of a drug is really available to exert its pharmacological action by interaction with the therapeutic target or is available to undergo elimination processes.
Protein binding has a main impact in multiple aspects that condition drug properties. Protein binding can influence the distribution, can reduce the metabolic clearance by the liver, can limit the blood brain barrier permeability, can influence dosing regimens… Therefore, the binding of a new compound to plasma proteins, to relevant tissue or to red blood cells is critical to understand its properties.
Species differences in plasma protein binding should also be known to explain differences in pharmacological activity or in safety, and for the prediction of human pharmacokinetics based on preclinical species data.
Caco-2 cells are a cell line derived from human colon adenocarcinoma with properties similar to intestinal epithelial cells, making them a widely used in vitro model for evaluating oral absorption of new compounds. These cells express the glycoprotein P (P-gp) and BCRP efflux transporters that may play an important role in limiting drug oral absorption.
The bi-directional transport assay with Caco-2 cells is one of the in vitro systems recommended by the Regulatory Agencies to assess the potential of an investigational drug to be a substrate of the P-gp and BCRP efflux transporters. Furthermore, permeability data can aid prioritize compounds during early stages of Drug Discovery and predict qualitatively in vivo oral absorption.
The study of the effect of the drug on metabolizing enzymes and relevant transporters is required in the assessment of drug interactions potential of new compounds.
In the case a new compound inhibits or induces enzymes involved in metabolism, such as the family of cytochromes P450 (CYP), the pharmacokinetics and/or the pharmacodynamics of a concomitant medication can be affected, leading to reduced efficacy or, on the contrary, to an exaggerated pharmacological effect or drug toxicity. This assessment is based on an in vitro evaluation of CYP inhibition in both, as reversible inhibition as well as time-dependent inhibition, and on an evaluation of CYP induction.
Interactions with transporters can also alter a concomitant drug’s disposition and, consequently, its pharmacological action. The inhibition of key efflux transporters involved in drug interactions with drugs in clinical use, such as P-gp and BCRP, should be studied.
Based on the in vitro data obtained in the mentioned studies, along with the estimated relevant concentration in vivo, the need of further in vivo evaluation can be assessed.
Quantitative LC-MS/MS analysis of new compounds and biomarkers across all key matrices—blood, plasma, serum, urine and tissues—to deliver the precise, reliable data you need to accelerate every stage of Drug Discovery and Development.
Is an emerging discipline that studies the interaction of drugs with the proteome, enabling a better understanding of mechanisms of action, resistance, and treatment toxicity. Its integration complements ADME-Tox and pharmacometabolomics studies, providing key information for the optimization of personalized therapies.
Selection of Proteins and Biomarkers
Is an emerging discipline that combines lipidomic analysis with pharmacology to better understand the interaction between drugs and the body’s lipid profiles. Its integration complements ADME-Tox and pharmacometabolomics studies, enabling a deeper characterization of compound bioavailability, metabolism, and toxicity.
Selection of Lipid Profiles and Biomarkers:
Is a key discipline in translational pharmacology, as it allows the analysis of drug impact on metabolism and helps understand variations in therapeutic response. Its integration enhances ADME-Tox studies and enables a more precise characterization of compound bioavailability, efficacy, and toxicity.
Selection of relevant Metabolites and Biomarkers
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. The assays in this panel include proteins involved in key biological processes such as cellular regulation, development, signal transduction and stress responses.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Oncology II features putative cancer-related human proteins that participate in biological mechanisms that are central to the initiation and progression of cancer, e.g. angiogenesis, cell-cell signaling, cell-cycle control, and inflammation.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Organ Damage features biomarkers involved in biological response to organ damage with a main focus on stress response, but also on regulation of cell proliferation, the cell cycle, and cell death/apoptosis.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Oncology III includes biomarkers involved in angiogenesis, cell communication, cellular metabolic processes, apoptosis and cell proliferation/differentiation. It is a perfect complement to our Olink® Target 96 Oncology II panel.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Inflammation features the most extensive commercially available biomarker selection for proteins associated with inflammatory diseases such as arthritis, chronic obstructive pulmonary disease, diabetes, psoriasis, and related biological processes. It is compiled to detect a selection of both established and exploratory biomarkers within the inflammation research field.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Metabolism includes biomarkers involved in cellular metabolic processes, cell surface receptor signaling pathways, regulation of phosphorylation and cell adhesion.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. The Olink® Target 96 Immuno-Oncology panel covers biomarkers related to immunotherapy/checkpoint molecules and biomarkers involved in promotion and inhibition of tumor immunity, chemotaxis, vascular & tissue remodeling, apoptosis & cell killing, and metabolism & autophagy.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Immune Response includes biomarkers involved in key biological processes such as adaptive immune response, defense response to viruses, lymphocyte activation, inflammatory responses and cytokine-mediated signaling pathways.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Cardiovascular II focuses on cardiovascular and inflammatory biomarkers which have been carefully selected in collaboration with leading experts in the field. It also includes a selection of exploratory proteins with potential as new CVD markers.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Neuro Exploratory consists of a combination of exploratory and established biomarkers with a focus on neurology-related diseases, and biological processes such as axon development, neurogenesis and synapse assembly. This panel is a good complement to Olink® Target 96 Neurology.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. The Olink® Target 96 Development panel focuses on biomarkers involved in cell communication and developmental processes.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Cell Regulation includes biomarkers involved in key biological processes such as cell communication, apoptotic processes, the cell cycle and cell differentiation.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. The Olink® Target 96 Neurology features well-established biomarkers related to neurobiological processes and neurological diseases (e.g. neural development, axon guidance, synaptic function, or specific conditions such as Alzheimer’s disease). Also includes additional exploratory proteins with broader roles in processes such as cellular regulation, immunology, development and metabolism.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Cardiometabolic features biomarkers involved in cellular metabolic processes, cell adhesion, immune response and complement activation. It is an excellent complement to Olink® Target 96 Cardiovascular II and Olink® Target 96 Cardiovascular III.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. As well as the cardiovascular, CVD, and exploratory protein markers included in Cardiovascular II, the Olink® Target 96 Cardiovascular III panel concentrates on cell adhesion biomarkers, carefully selected in collaboration with leading cardiovascular scientists.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 43 specific proteins. Olink® Target 48 Mouse Cytokine panel is a high-performance solution for protein multiplex studies in the murine model. The thorough selection of targeted biomarkers allows for a comprehensive view of the murine immune response, in-depth disease modelling and longitudinal studies in mice.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 44 specific proteins. Olink® Target 48 Immune Surveillance panel is a high-performance solution for immune response and inflammation-related studies. The carefully selected range of biomarkers in this panel provides a great mean for studying key pathways related to cytokine signalling, inflammatory processes, and immune response in cancer.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 45 specific proteins. Olink® Target 48 Cytokine panel is the high-performance solution for cytokine studies and inflammation-related diseases, with absolute or relative quantification. The thorough selection of biomarkers ensures that the most important proteins covering key pathways related to cytokine signaling and inflammatory processes are well covered.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 5 to 30 specific protein(s) selected from a library of 197 proteins, according to customer requirements.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 21 specific proteins. A panel targeting biomarkers involved in biological pathways central for immuno-oncology research e.g., angiogenesis, growth regulation, apoptosis and immunity.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 21 specific proteins. Assays carefully selected for their scientifically proven importance in the uncontrolled inflammatory response condition commonly referred to as cytokine storm.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 26 specific proteins. Includes 26 biomarkers crucial for studying inflammation and providing deeper insights into the immune landscape.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 21 specific proteins. Curated based on UK Biobank proteomics data to include top biomarkers associated with type 2 diabetes.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 21 specific proteins. Aging is a multifaceted process characterized by systemic chronic inflammation. This carefully curated panel includes biomarkers crucial in age-related changes of the immune system.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 20 specific proteins. Interferon (IFN) inflammation is associated with immunotherapy resistance in melanoma. This panel is developed together with Dr. Mehta and is based on findings from the Nature Immunology paper “In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer” (Manguso et al.)
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 5 specific proteins. Combines 5 key proinflammatory markers for targeted studies of inflammation and immune response.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 21 specific proteins. This panel includes the most important cytokines characterizing the Th1/Th2/Th17 inflammatory profiles, thereby providing the ultimate solution for studies of the immune system.
More applications: Health & Medicine | Agriculture & Food | Cosmetics & Dermatology | Nutraceutical & Nutrition | Veterinary & Animal Science | Environmental & Ecology
Transform your omics data into actionable insights with oloMAP Portal, our interactive platform for advanced statistical analysis and visualization.
Combine multiple omics datasets to uncover relationships between biological layers, gain a holistic view of underlying processes and identify potential biomarkers.
Comprehensive biological interpretation from our experts to connect omics data with biological pathways, highlighting relevant mechanisms and potential biomarkers tailored to your study.
01
Contact and
Proposal
02
Send Samples
to the Lab
03
Sample Reception
and Processing
04
Mass Spectrometry
Analysis
05
Gain Insight into
oloMAP Portal
Standard Delivery Time:
6 weeks
Fast-track option available
Minimum Sample Amount:
Consult our experts for guidance
on sample requirements
Discount:
Associated with the number of
samples and multi-omics analysis
Partner with us to explore the power of omics in your field. Our team is ready to guide you through the process and deliver insights tailored to your research or industry needs.
Contact us today to discuss your project or schedule a consultation. Together, we’ll advance innovation through omics!